

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

Technical Data Sheet

Human EphA2 (C-His-Avi)

Catalog Number: 814301, 814302

Size: 25 ug, 100 ug Target Name: EphA2 Regulatory Status: RUO

Product Details

Application: ELISA, BLI Format: Liquid, Purified Expression Host: CHO

Species: Human

Sources: Recombinant Human EphA2 (Gln25-Asn534) with C-terminus His-Avi-tag is expressed in

CHO cell.

Accession Number: P29317

Molecular Weight: The protein has a predicted molecular weight of 59.7 kDa. Under DTT-reducing

conditions, it migrates at approximately 65 kDa on SDS-PAGE.

Affinity Tag: C-His-Avi

Purity: >95% based on SDS-PAGE under reducing condition

Formulation: 1xPBS buffer, pH7.4, 0.22 µm filtered

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a

lot-specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4° C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 μ m-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at <= -70° C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information


EphA2 (Ephrin type-A receptor 2) is a receptor tyrosine kinase involved in cell adhesion, migration, and tissue organization. It plays a critical role in embryonic development and angiogenesis. EphA2 is frequently overexpressed in various cancers, including breast, lung, and prostate cancer. Overexpression is associated with increased tumor growth, invasiveness, and poor clinical outcomes. Because of its role in promoting tumor progression, EphA2 is being actively explored as a therapeutic target in oncology. Therapeutic strategies include monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates targeting EphA2-positive tumors.

Product Data



InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618



Human EphA2 (C-His-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.